{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:25:29Z","timestamp":1791516329700,"version":"4.3.4"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Accumulating evidence suggests that hyperbaric oxygen therapy (HBOT) may be effective for inflammatory bowel disease (IBD). Our systematic review aimed to quantify the effectiveness and safety of HBOT in various IBD phenotypes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a proportional meta-analysis. Multiple databases were systematically searched from inception through November 2020 without language restriction. We included studies that reported effectiveness and\/or safety of HBOT in IBD. Weighted summary estimates with 95% confidence intervals (Cis) were calculated for clinical outcomes for each IBD phenotype using random-effects models. Study quality was assessed using the Cochrane evaluation handbook and National Institute of Health criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nineteen studies with 809 patients total were eligible: 3 randomized controlled trials and 16 case series. Rates of clinical remission included 87% (95% CI, 10\u2013100) for ulcerative colitis (n\u2005=\u200542), 88% (95% CI, 46\u201398) for luminal Crohn\u2019s disease (CD, n\u2005=\u20058), 60% (95% CI, 40\u201376) for perianal CD (n\u2005=\u2005102), 31% (95% CI, 16\u201350) for pouch disorders (n\u2005=\u200560), 92% (95% CI, 38\u2013100) for pyoderma gangrenosum (n\u2005=\u20055), and 65% (95% CI, 10\u201397) for perianal sinus\/metastatic CD (n\u2005=\u20057). Of the 12 studies that reported on safety, 15% of patients (n\u2005=\u200530) had minor adverse events. Study quality was low in the majority of studies due to an absence of comparator arms, inadequate description of concomitant interventions, and\/or lack of objective outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Limited high-quality evidence suggests that HBOT is safe and associated with substantial rates of clinical remission for multiple IBD phenotypes. Well-designed randomized controlled trials are warranted to confirm the benefit of HBOT in IBD.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ibd\/izab098","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T12:59:38Z","timestamp":1621342778000},"page":"611-621","source":"Crossref","is-referenced-by-count":27,"title":["The Effectiveness and Safety of Hyperbaric Oxygen Therapy in Various Phenotypes of Inflammatory Bowel Disease: Systematic Review With Meta-analysis"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0658-3062","authenticated-orcid":false,"given":"Jeffrey","family":"McCurdy","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Faculty of Medicine, University of Ottawa , Ontario, Canada"},{"name":"The Ottawa Hospital Research Institute , Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Chin Koon","family":"Siw","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Faculty of Medicine, University of Ottawa , Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Kandel","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Faculty of Medicine, University of Ottawa , Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larrigan","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Research Institute , Ottawa, Ontario, Canada"},{"name":"Faculty of Medicine, University of Ottawa , Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University of British Columbia , British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Boet","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Research Institute , Ottawa, Ontario, Canada"},{"name":"Department of Anesthesiology and Pain Medicine, Hyperbaric medicine unit; Francophone Affairs, Faculty of Medicine, University of Ottawa , Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"2022092317583361200_CIT0001","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial","volume":"371","author":"D\u2019Haens","year":"2008","journal-title":"Lancet."},{"key":"2022092317583361200_CIT0002","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med."},{"key":"2022092317583361200_CIT0003","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology."},{"key":"2022092317583361200_CIT0004","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet."},{"key":"2022092317583361200_CIT0005","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"2022092317583361200_CIT0006","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"2022092317583361200_CIT0007","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/gutjnl-2019-318440","article-title":"Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study","volume":"69","author":"Murthy","year":"2020","journal-title":"Gut."},{"key":"2022092317583361200_CIT0008","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/apt.12873","article-title":"The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study","volume":"40","author":"Reich","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092317583361200_CIT0009","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/ajg.2012.333","article-title":"Decreasing colectomy rates for ulcerative colitis: a population-based time trend study","volume":"107","author":"Kaplan","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"2022092317583361200_CIT0010","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/apt.12753","article-title":"Systematic review: the safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease","volume":"39","author":"Dulai","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092317583361200_CIT0011","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2045-9912-2-6","article-title":"Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis","volume":"2","author":"Rossignol","year":"2012","journal-title":"Med Gas Res."},{"key":"2022092317583361200_CIT0012","first-page":"176","article-title":"Essentials of hyperbaric oxygen therapy: 2019 review","volume":"116","author":"Kirby","year":"2019","journal-title":"Mo Med."},{"key":"2022092317583361200_CIT0013","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.biopha.2018.10.142","article-title":"Hyperbaric oxygen therapy: antimicrobial mechanisms and clinical application for infections","volume":"109","author":"Memar","year":"2019","journal-title":"Biomed Pharmacother."},{"key":"2022092317583361200_CIT0014","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1100\/tsw.2006.78","article-title":"Effects of hyperbaric oxygen on inflammatory response to wound and trauma: possible mechanism of action","volume":"6","author":"Al-Waili","year":"2006","journal-title":"Scientificworldjournal."},{"key":"2022092317583361200_CIT0015","author":"Higgins","year":"2016"},{"key":"2022092317583361200_CIT0016","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med."},{"key":"2022092317583361200_CIT0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.22462\/01.03.2019.5","article-title":"Hyperbaric oxygen therapy for the treatment of perianal fistulas in Crohn\u2019s disease (HOT-TOPIC): study protocol of a prospective interventional cohort study with one-year follow-up","volume":"46","author":"Lansdorp","year":"2019","journal-title":"Undersea Hyperb Med."},{"key":"2022092317583361200_CIT0018","author":"National Institutes of Health (2014)"},{"key":"2022092317583361200_CIT0019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials."},{"key":"2022092317583361200_CIT0020","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence\u2013inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol."},{"key":"2022092317583361200_CIT0021","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41395-018-0005-z","article-title":"Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial","volume":"113","author":"Dulai","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2022092317583361200_CIT0022","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/apt.15984","article-title":"A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares","volume":"52","author":"Dulai","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092317583361200_CIT0023","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3109\/00365521.2013.819443","article-title":"Hyperbaric oxygen therapy does not improve the effects of standardized treatment in a severe attack of ulcerative colitis: a prospective randomized study","volume":"48","author":"Pagoldh","year":"2013","journal-title":"Scand J Gastroenterol."},{"key":"2022092317583361200_CIT0024","doi-asserted-by":"crossref","first-page":"FSO77","DOI":"10.4155\/fso.15.77","article-title":"Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn\u2019s disease","volume":"1","author":"Agrawal","year":"2015","journal-title":"Future Sci OA."},{"key":"2022092317583361200_CIT0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/codi.12500","article-title":"Healing under pressure: hyperbaric oxygen and myocutaneous flap repair for extreme persistent perineal sinus after proctectomy for inflammatory bowel disease","volume":"16","author":"Chan","year":"2014","journal-title":"Colorectal Dis."},{"key":"2022092317583361200_CIT0026","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/BF02054120","article-title":"Hyperbaric oxygenation in severe perineal Crohn\u2019s disease","volume":"38","author":"Colombel","year":"1995","journal-title":"Dis Colon Rectum."},{"key":"2022092317583361200_CIT0027","article-title":"Hyperbaric oxygen therapy is effective in the treatment of inflammatory and fistulizing pouch complications","author":"Fahad","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092317583361200_CIT0028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1590\/S0102-86502016001300005","article-title":"Adjunctive hyperbaric oxygen therapy promotes successful healing in patients with refractory Crohn\u2019s disease","volume":"31 Suppl 1","author":"Feitosa","year":"2016","journal-title":"Acta Cir Bras."},{"key":"2022092317583361200_CIT0029","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(17)31599-8","article-title":"Could the hyperbaric oxygen therapy be an effective adjuvant therapy for fistulising Crohn\u2019s disease?","volume-title":"J Crohn\u2019s Colit","author":"Piotrowicz","year":"2017"},{"key":"2022092317583361200_CIT0030","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaa245","article-title":"Hyperbaric oxygen therapy in chronic inflammatory conditions of the pouch","author":"Hasan","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2022092317583361200_CIT0031","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1590\/S0102-86502011000800024","article-title":"Crohn\u2019s disease and hyperbaric oxygen therapy","volume":"26 Suppl 2","author":"Iezzi","year":"2011","journal-title":"Acta Cir Bras."},{"key":"2022092317583361200_CIT0032","first-page":"78","article-title":"Hyperbaric oxygenation as a part of the treatment of chronic ulcerohemorrhagic colitis","volume":"30","author":"Kark\u016dmov","year":"1991","journal-title":"Vutr Boles."},{"key":"2022092317583361200_CIT0033","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1177\/2050640620934915","article-title":"Wound healing of metastatic perineal Crohn\u2019s disease using hyperbaric oxygen therapy: a case series","volume":"8","author":"Lansdorp","year":"2020","journal-title":"United European Gastroenterol J."},{"key":"2022092317583361200_CIT0034","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00004836-199410000-00006","article-title":"Hyperbaric oxygen for perianal Crohn\u2019s disease","volume":"19","author":"Lavy","year":"1994","journal-title":"J Clin Gastroenterol."},{"key":"2022092317583361200_CIT0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1023\/A:1027378532003","article-title":"Modification of in vivo and in vitro TNF-alpha, IL-1, and IL-6 secretion by circulating monocytes during hyperbaric oxygen treatment in patients with perianal Crohn\u2019s disease","volume":"17","author":"Weisz","year":"1997","journal-title":"J Clin Immunol."},{"key":"2022092317583361200_CIT0036","doi-asserted-by":"crossref","first-page":"e000082","DOI":"10.1136\/bmjgast-2016-000082","article-title":"Hyperbaric oxygen therapy stimulates colonic stem cells and induces mucosal healing in patients with refractory ulcerative colitis: a prospective case series","volume":"3","author":"Bekheit","year":"2016","journal-title":"BMJ Open Gastroenterol."},{"key":"2022092317583361200_CIT0037","first-page":"132","article-title":"Experience of preservation remission in inflammatory bowel diseases","volume":"9","author":"Grigor\u2019eva","year":"2011","journal-title":"Eksp Klin Gastroenterol."},{"key":"2022092317583361200_CIT0038","article-title":"Tu1340 hyperbaric oxygen therapy in the management of refractory Crohn\u2019s disease","volume-title":"Gastroenterology","author":"Keihanian","year":"2015"},{"key":"2022092317583361200_CIT0039","first-page":"120","article-title":"[Hyperbaric oxygenation and drug therapy in treatment of nonspecific ulcerative colitis and Crohn\u2019s disease]","volume":"37","author":"Poliakova","year":"1991","journal-title":"Fiziol Zh."},{"key":"2022092317583361200_CIT0040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/wound.2016.0718","article-title":"Hyperbaric oxygen therapy: side effects defined and quantified","volume":"6","author":"Heyboer","year":"2017","journal-title":"Adv Wound Care (New Rochelle)."},{"key":"2022092317583361200_CIT0041","first-page":"217","article-title":"Middle-ear barotrauma after hyperbaric oxygen therapy: a five-year retrospective analysis on 2610 patients","volume":"47","author":"Edinguele","year":"2020","journal-title":"Undersea Hyperb Med."},{"key":"2022092317583361200_CIT0042","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","article-title":"Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial","volume":"388","author":"Pan\u00e9s","year":"2016","journal-title":"Lancet."},{"key":"2022092317583361200_CIT0043","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.15665","article-title":"Vedolizumab for perianal Crohn\u2019s disease: a multicentre cohort study in 151 patients","volume":"51","author":"Chapuis-Biron","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092317583361200_CIT0044","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.14309\/ajg.0000000000000810","article-title":"Ustekinumab for perianal crohn\u2019s disease: the BioLAP multicenter study from the GETAID","volume":"115","author":"Chapuis-Biron","year":"2020","journal-title":"Am J Gastroenterol."},{"key":"2022092317583361200_CIT0045","doi-asserted-by":"crossref","first-page":"e0237746","DOI":"10.1371\/journal.pone.0237746","article-title":"Integrin-mediated adhesive properties of neutrophils are reduced by hyperbaric oxygen therapy in patients with chronic non-healing wound","volume":"15","author":"Baiula","year":"2020","journal-title":"Plos One."},{"key":"2022092317583361200_CIT0046","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000339613","article-title":"Wound repair and regeneration","volume":"49","author":"Reinke","year":"2012","journal-title":"Eur Surg Res."},{"key":"2022092317583361200_CIT0047","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2337\/dc17-0654","article-title":"Hyperbaric oxygen therapy in the treatment of ischemic lower- extremity ulcers in patients with diabetes: results of the DAMO2CLES multicenter randomized clinical trial","volume":"41","author":"Santema","year":"2018","journal-title":"Diabetes Care."},{"key":"2022092317583361200_CIT0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.22462\/1.2.2017.1","article-title":"Hyperbaric medicine today: an historically noble discipline challenged by loss of critical access and overutilization \u2013 an introduction to invited commentary","volume":"44","author":"Huang","year":"2017","journal-title":"Undersea Hyperb Med."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/4\/611\/45985430\/izab098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/4\/611\/45985430\/izab098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T21:24:26Z","timestamp":1699046666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/28\/4\/611\/6277724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,5,18]]},"published-print":{"date-parts":[[2022,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izab098","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,5,18]]}}}